Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2019 10:00 ET | Source: MolecularMD

MolecularMD is acquired by ICON

PORTLAND, Ore. and CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- MolecularMD Corporation, a molecular diagnostic specialty laboratory that enables the development and commercialisation of...
November 28, 2018 03:00 ET | Source: MolecularMD

Sysmex and MolecularMD Commence Global Partnership to Address the Challenges in Companion Diagnostics Development and Commercialization

PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), a Japanese in vitro diagnostics company, and...
November 13, 2018 00:00 ET | Source: MolecularMD

First quantitative diagnostic test validated for Treatment-Free Remission for Eligible Patients with Ph+ CML-CP Treated with Tasigna® Cleared by Health Canada

PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation received regulatory approval from Health Canada for the MRDx® BCR-ABL Test, a quantitative diagnostic...
August 22, 2018 05:00 ET | Source: MolecularMD

MolecularMD Launches Validated Tumor Mutation Burden Assay for Immuno-Oncology Clinical Trial Services

PORTLAND, Ore., Aug. 22, 2018 (GLOBE NEWSWIRE) -- MolecularMD today announces it has validated Thermo Fisher Scientific’s Oncomine™ Tumor Mutation Load Assay for clinical research trials to aid...
June 04, 2018 00:30 ET | Source: MolecularMD

MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®

PORTLAND, Ore. and CARLSBAD, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation and Genoptix, Inc. announced today that they have entered into an exclusive agreement to market and...
December 22, 2017 18:02 ET | Source: MolecularMD

MolecularMD obtains FDA Authorization for the MRDx® BCR-ABL Test as a Companion Diagnostic for Treatment-Free Remission in Ph+ CML-CP Patients Treated with Tasigna

PORTLAND, Ore. and CAMBRIDGE, Mass., Dec. 22, 2017 (GLOBE NEWSWIRE) -- MolecularMD Corporation, a diagnostics company that enables the development and commercialization of precision medicines in...
November 13, 2017 20:00 ET | Source: MolecularMD

MolecularMD to Implement Promega’s Microsatellite Instability (MSI) Technology for Immuno-Oncology Applications

PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- MolecularMD announces that it has now become a Preferred Provider of Promega’s Microsatellite Instability (MSI) v1.2 Analysis...
September 28, 2017 20:00 ET | Source: MolecularMD

MolecularMD Announces Partnership with Indica Labs to Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services

PORTLAND, Ore. and CAMBRIDGE, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- MolecularMD, a provider of molecular and tissue-based clinical trial assays and diagnostics for oncology based drug...
June 01, 2017 05:00 ET | Source: MolecularMD

MolecularMD achieves status as an ArcherDX Certified Service Provider and expands offering of novel NGS chemistries

PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - June 01, 2017) - MolecularMD Corp., a molecular diagnostics company that provides clinical trial services and development of companion diagnostics for...
February 15, 2017 10:00 ET | Source: MolecularMD

Asterand Bioscience and MolecularMD announce a partnership to accelerate targeted therapeutic biomarker validation, optimization, development and commercialization

PORTLAND, OR and CAMBRIDGE, MA and DETROIT, MI--(Marketwired - February 15, 2017) - Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research...

Next Page keyboard_arrow_right